Posted by AGORACOM-JC
at 9:19 AM on Friday, March 12th, 2021
SPONSOR: The Liquid Avatar Technologies (LQID: CSE) Mobile App, available in the Apple App Store and Google Play is a verified Self Sovereign Identity platform that empowers users to create high quality digital icons representing their online personas. These icons allow users to manage and control their digital identity and Verifiable Access and Identity Credentials, and to use Liquid Avatars to share public and permission based private data when they want and with whom they want. www.liquidavatar.com.
Posted by AGORACOM-JC
at 8:54 AM on Wednesday, March 10th, 2021
Liquid Avatar Technologies (LQID: CSE) and ImagineAR (IP:CSE / IPNFF:OTCQB) are incredibly disruptive and on the cusp of unstoppable trends, which makes them both explosive but also so new that investors still need to wrap their minds around each of them, let alone both of them together. The good news is that CEO’s from both companies (David Lucatch Liquid Avatar and Alen Paul Silverrstieen ImagineAR) have sat down with us to explain why their combination is the way all of us will be controlling and profiting from our online identities in the near future.
Before watching the video, here is a little about what you need to know about each company.
LIQUID AVATAR – Solves the major problem around our online identities and data. Through Liquid Avatar they provide each one of us with the power to manage and monetize our digital identity, which is an unstoppable trend as both a natural evolution of the web, as well as, legislation forcing big platforms to no longer share and profit from our personal online data.
IMAGINEAR – As the name implies, ImagineAR is an Augmented Reality Company that enables businesses to create their own mobile phone AR campaigns with no programming or technology experience. AR is also an unstoppable trend – but don’t take our word for it.
Apple CEO Tim Cook stated “AR Will play an important role in how we use technology in the future – and promises to be as influential in our society as the smart phone”
The AR market is expected to grow to $200 Billion by 2025 from just $3.5 billion in 2017. .
Now you know why the combination of these two companies is so powerful and well worth your while to watch, listen and learn about what they are going to do. The future is coming, so you might as well see it coming first.
Posted by AGORACOM-JC
at 5:36 PM on Tuesday, March 9th, 2021
Loop Insights was selected by bdG Sports to provide its venue management platform to the Big West Conference Men’s and Women’s Basketball Championships being held March 9-13, 2021 at the Mandalay Bay Events Center in Las Vegas.
bdG Sports CEO Brooks Downing stated: “Following the success of the Gulf Coast Showcase and the Vegas Main Event, Loop Insights was the obvious choice to provide its venue management platform to the Big West Championships at the Mandalay Bay in Las Vegas. We look forward to continuing our partnership with Loop Insights as we continue to provide safe and secure venues for NCAA athletes as they demonstrate their skills in preparation for the NCAA’s March Madness tournament.”
Loop Insights CEO Rob Anson stated: “Loop Insights is proud to be selected once again as the venue management provider for bdG Sports and the Big West Conference Championships. The successful deployments of our venue management platform at the Gulf Coast Showcase and Vegas Main Event clearly demonstrate our ability to secure any venue through our complete end-to-end venue management solution. We look forward to working with bdG Sports once again to protect NCAA athletes, coaches, and staff.”
Watch this powerful interview with Loop Insights CEO Rob Anson and bdG Sports CEO Brooks Downing.
Posted by AGORACOM-JC
at 8:29 AM on Monday, March 1st, 2021
$1.29 million in fiscal second quarter revenue
Clinics see continued surge in demand for mental health services
Ongoing expansion of clinic capacity
TORONTO, ON / March 1, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF) (“Novamind” or “the Company”), a leading mental health company specialized in psychedelic medicine, today reported its fiscal second quarter results for the three months ended December 31, 2020 (“Fiscal Q2 2021″). The Company’s fiscal year-end is June 30th. All results are reported under International Financial Reporting Standards (“IFRS”) and in Canadian dollars, unless otherwise specified.
Fiscal Q2 2021 Highlights and Subsequent Developments
Financing and Public Listing
Novamind successfully closed an oversubscribed $10,000,000 financing on November 23rd, 2020. The funds were made available to the Company upon the completion of its reverse takeover (“RTO”) transaction and conditional listing approval from the Canadian Securities Exchange (“CSE”). The company ended the quarter with a cash balance of $10,868,742. With its strong cash position, Novamind is well-positioned to execute on its growth strategy to expand its network of mental health clinics, retreats and clinical research sites.
On January 5th, 2021, Novamind began trading on the CSE under the stock symbol “NM”. Less than two months after going public on the CSE, Novamind achieved the milestone of being included in the underlying index of the Horizons Psychedelic Stock Index ETF (NEO: PSYK) through a “Fast Entry” category, further increasing its profile with retail and institutional investors in the psychedelic medicine sector.
The Company announced on February 19th, 2021, that its common shares commenced trading under the symbol “NVMDF” on the OTC Market. In the near future, Novamind intends to apply to list its common shares on the OTCQB Market, an established marketplace in the United States for promising, innovative companies.
Operational Highlights
On January 28th, 2021, Novamind announced that it had reached two significant milestones at its Cedar Psychiatry mental health clinics: administering over 5,000 ketamine treatments since its opening in 2016, and administering over 2,000 Spravato™ treatments since the product became available in 2019. These milestones position Novamind as one of North America’s top providers of ketamine-assisted psychotherapy and Spravato™.
On January 13th, 2021, the Company announced the expansion and optimization of its Layton, Utah clinic. The redesigned Layton Clinic now offers improved treatment rooms to accommodate a higher number of ketamine and Spravato™ treatments. The Layton Clinic expansion comes in response to a significant increase in demand for ketamine therapies across Novamind’s mental health clinics. In 2020 alone, the Cedar Psychiatry clinic network facilitated over 20,000 client visits, an increase of over 100 percent compared to the same period in 2019.
On January 19th, 2021, Novamind announced the expansion of its leadership team with the appointment of Pierre Bou-Mansour, P.Eng., to the role of Chief Operating Officer. Mr. Bou-Mansour assumes the responsibility for ensuring operational excellence as Novamind develops its network of clinics, retreats, and research sites. An accomplished senior executive and leader, he brings a wealth of experience managing large and complex healthcare organizations. Prior to joining Novamind, Pierre served as the Chief Operating Officer of LifeLabs, a diagnostic laboratory services company he helped to scale into an industry leader with 5,700 employees and 370 patient access sites in Canada. Most recently, he served as the Chief Laboratory Operations Officer of Public Health Ontario, serving Canada’s largest province with over 14 million residents. In this role, Bou-Mansour successfully led the expansion of Public Health Ontario’s testing capacity for the COVID-19 response.
Strategic Investment in Bionomics
On February 11th, 2021, the Company announced that it had made a strategic investment of AU$827,486 (approximately CAN$810,000), in Bionomics Limited (“Bionomics”) (ASX: BNO, OTCQB: BNOEF, Germany: AU000000BNO5), a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders. In addition, Cedar Clinical Research, a wholly owned subsidiary of Novamind, will be evaluated by Bionomics as a clinical research site to conduct Bionomics’ phase IIb clinical trial examining BNC210, a drug that has received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of post-traumatic stress disorder (PTSD).
Impact of COVID-19
Novamind has not been significantly affected by the COVID-19 pandemic. As reported across multiple media outlets, the COVID-19 pandemic has resulted in a significant increase in the incidence of mental health problems, in particular anxiety and depression, conditions that are commonly treated by Novamind. The Company’s Cedar Psychiatry network of clinics continues to experience steady demand for mental health services, and this demand is anticipated to continue despite COVID-related restrictions.
Financial Highlights and Selected Consolidated Financial Information
In Fiscal Q2 2021, Novamind reported revenue of $1,288,828 primarily composed of patient services revenue from its network of four Cedar Psychiatry outpatient mental health clinics in Utah. This represents a 47 percent increase over the previous quarter ended September 30th, 2020.
The Company reported a net loss of $3,567,883 for the three months ended December 31st, 2020, as compared to a net loss of $493,614 for the prior quarter ended September 30th, 2020. The net loss for the second fiscal quarter was primarily due to expenses related to the Company’s listing on the CSE, and funding of capacity expansion at its Cedar Psychiatry clinics. This includes consulting expenses of $416,268, professional fees of $450,419, salaries and wages of $791,078, office and general expenses of $87,368, advertising and promotion expenses of $236,650, and stock-based compensation of $664,814. Additionally, there was $1,379,144 in RTO transaction costs in the quarter.
The following table presents selected financial information from the Company’s unaudited condensed interim financial statements for the three and six months ended December 31st, 2020, and periods ended December 31st, 2019.
The following information should be read in conjunction with the financial statements and management’s discussion and analysis, which are available under the Company’s SEDAR profile at www.sedar.com.
About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.
Posted by AGORACOM-JC
at 6:11 PM on Friday, February 26th, 2021
PlantX Life Inc. (VEGA: CSE) (PLTXF: OTCQB) announces massive partnerships With Alicia Silverstone and Venus Williams. Did we mention that Russell Peters attended the AGM?
Posted by AGORACOM-JC
at 12:08 PM on Tuesday, February 23rd, 2021
Announced its participation in the Benzinga Cannabis Capital Conference, on February 25th and 26th, 2021, one of the select companies to be featured from the emerging psychedelics industry.
On Friday, February 26th, 2021 at 1:30pm EST, Novamind’s CEO and Director, Yaron Conforti, will present the Company’s vision for scaling access to psychedelic medicine and advancing clinical research.
TORONTO, ON / February 23, 2021 / Novamind Inc. (CSE:NM) (OTC PINK:NVMDF) (“Novamind” or “the Company”), a leading mental health company specialized in psychedelic medicine, is pleased to announce its participation in the Benzinga Cannabis Capital Conference (“the Conference”), on February 25th and 26th, 2021, one of the select companies to be featured from the emerging psychedelics industry.
On Friday, February 26th, 2021 at 1:30pm EST, Novamind’s CEO and Director, Yaron Conforti, will present the Company’s vision for scaling access to psychedelic medicine and advancing clinical research.
“We are excited to connect with investors who share our belief that innovative mental health therapies are disrupting the current standard of care in mental health,” said Yaron Conforti, CEO and Director of Novamind. “I look forward to this opportunity to share Novamind’s approach to mental healthcare and clinical research in psychedelic medicine.”
The Conference will also host a panel discussion on psychedelics with industry leaders including Novamind’s Chief Medical Officer, Dr. Reid Robison on Friday, February 26th, 2021 at 1:50pm EST.
For more information about the conference, please click here.
About Novamind Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.
Contact Information:
Novamind Yaron Conforti, CEO and Director Telephone: +1 (647) 953 9512
Forward-Looking Statements This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.
Posted by AGORACOM-JC
at 5:27 PM on Thursday, February 18th, 2021
When we conduct a “Beyond The Press Release” interview, it is always about A press release …. but Empower Clinics has been moving so fast that we sat down with CEO Steve McAuley to discuss these THREE press releases, the explosive growth of the Company and where it is going:
Partnership With Rexall To Launch Integrated Health Centres
Surpassed 1,000 COVID-19 tests on 1 day for first time ever … 3X Lab Expansion
Secured Medical Device Establishment License (MDEL) To Sell KAI Saliva
As usual, Six Sigma Steve McAuley doesn’t disappoint as he confidently and clearly tells investors where Empower Clinics is going next.
Tags: covid19, Covid19 testing, CSE, Diagnos Inc, investments Posted in Empower Clinics Inc., Featured | Comments Off on VIDEO – As Empower Clinics $CBDT.ca $EPWCF Makes New Highs On Multiple Major Announcements, CEO McAuley Discusses Why $100M Clinic Revenue Is Stage 1 – And Much More Is Coming $WELL.ca $DOC.ca $DOCRF $VMD.ca
Posted by AGORACOM-JC
at 9:57 AM on Thursday, February 18th, 2021
ISBRG is a data analytics company which has developed the SpotLight technology platform designed to generate comprehensive health care data non-invasively within seconds at a nominal incremental cost per test.
“Our technology stems from the belief that technological innovation and strategic partnerships will restore economic growth globally in the midst of a pandemic that is challenging the speed, accuracy and effectiveness of existing tests” stated Duncan MacIntyre, Founder and CEO ISBRG.
The global Covid-19 diagnostics market size is estimated at USD$84.4 billion in 2020 and is expected to expand at a compounded annual growth rate (CAGR) of 3.1% from 2021 to 2027[1].
ISBRG founder Duncan MacIntyre, is the former President of ICI in Canada and Latin America, the founding President of the National Quality Institute and co-author of more than 25 US patents in the field of spectroscopy. He has assembled a team of medical doctors, Ai specialists, hardware designers, internationally recognized optics experts and an ISBRG Board of Advisors that excel in their respective fields. The Board of Advisors includes:
former Global VP of AMGEN – Michael Kelly
former Canadian Astronaut and Author – Commander Chris Hadfield
former Director of Emera and Order of Canada appointee – Irene d’Entremont
former President of American Eagle Airlines – Peter Bowler
former Director General Global Operations CSIS – Allan MacDougall
Posted by AGORACOM-JC
at 8:31 AM on Thursday, February 18th, 2021
Kai Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, TX was acquired by Empower Clinics on October 6, 2020 to further advance the Company’s COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and travel industry
Announced KAI Medical Laboratory has validated that its various COVID-19 PCR test products are able to accurately detect the B.1.1.7 (UK variant) & B.1.351 (South African variant)
VANCOUVER BC / February 18, 2021 /EMPOWER CLINICS INC.(CSE:CBDT)(OTCQB:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“) an integrated healthcare company serving patients through medical centres, telemedicine platforms, operating a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce our KAI Medical Laboratory (“KAI LAB”) has validated that its various COVID-19 PCR test products are able to accurately detect the B.1.1.7 (UK variant) & B.1.351 (South African variant).
“The Kai Labs motto of Inspire by Science, Built on Integrity is displayed so accurately as the team of molecular scientists took it upon themselves to validate our test protocols against pervasive new COVID-19 variants.” said Steven McAuley, Chairman & CEO. “Leading with science, continuous improvement and a desire to impact healthcare outcomes elevates Kai Labs to a national and international stage. I expect this to be a competitive advantage as we endeavour to sign new global distribution and sales contracts.”
World Health Organization (WHO) Chief Scientist Confirms The U.K. Variant and South African Variants Are a Concern
Dr. Soumya Swaminathan comments “…scientists have now studied this and have found that these variants do tend to spread faster, they’re more transmissible or more infectious. So that’s the worrying part.”
KAI Medical Laboratory Research & Development a key differentiator for the Future
The KAI Lab testing protocol tests for parts of the viral genome that is not affected by the mutations in the spike protein the “S’ gene. In effect, this ensures the active virus in a patient’s RNA genetic sequence can be detected and a correct test result will be provided.
Dr. Soumya Swaminathan indicates “We know that testing, that identifying those who are infectious, that being able to provide them supportive isolation, tracking and contact tracing, and quarantining all the contacts…All of these things together definitely make a difference in bringing down transmission.”
Tags: covid19, Covid19 testing, CSE, Diagnos Inc, investments Posted in Empower Clinics Inc., Featured | Comments Off on Empower Clinics $CBDT.ca $EPWCF KAI Medical Laboratory Demonstrates Significant Scientific Capability by Validating its PCR Tests Accurately Detect COVID-19 U.K. and South Africa Variants $WELL.ca $DOC.ca $DOCRF $VMD.ca
